Keyphrases
Small Interfering RNA (siRNA)
100%
Chemoresistant
100%
Cisplatin
100%
Nanodelivery
100%
Breast Cancer
100%
REV3
66%
Nanocarriers
50%
Breast Cancer Treatment
50%
PLGA-PEG
33%
Chemosensitivity
33%
Physicochemical Properties
33%
Enhanced Cancer Therapy
16%
Chemoresistance
16%
Lipid Compounds
16%
Disease Targets
16%
Lipid-polymer Hybrid Nanoparticles
16%
Recurrent Disease
16%
Implantable Drug Delivery
16%
Platinum-based
16%
Drug Regimen
16%
Breast Tumor
16%
FDA-approved Drugs
16%
Synergistic Effect
16%
Polymer Degradation
16%
Cationic Lipids
16%
Poly(lactide-co-glycolide)
16%
Breast Cancer Patients
16%
Early Breast Cancer
16%
Acquired Resistance
16%
Injectable Drug Delivery
16%
Gene-specific
16%
Induced mutation
16%
Crucial Genes
16%
Translesion DNA Polymerase
16%
Hybrid NPs
16%
Breast Cancer Biology
16%
RNA Therapeutics
16%
Unique Mechanism
16%
Relapsed Tumor
16%
Breast Cancer Cases
16%
Cell Capacity
16%
Subsequent Therapy
16%
Therapeutic Outcome
16%
Single Polymer
16%
Chemotherapy-induced
16%
Drug Diffusion
16%
RNA-based
16%
Two-in-one
16%
Polymer Drugs
16%
Nanotherapeutics
16%
Gene Products
16%
DNA Damage
16%
Early Detection
16%
Underserved
16%
Quality of Life
16%
Delivery System
16%
Biocompatibility
16%
Tumor
16%
Biodegradable Materials
16%
Therapeutic Strategies
16%
Controlled Release
16%
Clinically Significant
16%
Drug Delivery System
16%
Long History
16%
Tumor Cells
16%
Copolymer
16%
Polyethylene Glycol
16%
Pharmacology, Toxicology and Pharmaceutical Science
Small Interfering RNA
100%
Breast Cancer
100%
Cisplatin
100%
Polyethylene Glycol
37%
Nanocarrier
37%
Neoplasm
37%
Breast Tumor
12%
Recurrent Disease
12%
Chemotherapy
12%
DNA Polymerase
12%
Copolymer
12%
Polyglactin
12%
Controlled Release
12%
Macrogol
12%
Drug Resistance
12%
Nanoparticle
12%
Drug Delivery System
12%
Macrogol Derivative
12%
Diseases
12%